Predictors of treatment initiation with tumor necrosis factor-A inhibitors in patients with rheumatoid arthritis

Journal of Managed Care and Specialty Pharmacy

Volumn 20, Issue 11, 2014, Pages 1110-1120

  Desai, Rishi J ^a   Rao, Jaya K ^b   Hansen, Richard A ^c   Fang, Gang ^d   Maciejewski, Matthew L ^e   Farley, Joel F ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Annals of Internal Medicine   (United States)

^d AUBURN UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; CERTOLIZUMAB; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ANALGESIA; ARTICLE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; FEMALE; FOLLOW UP; GEOGRAPHY; HEALTH CARE ACCESS; HEALTH DISPARITY; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; MONOTHERAPY; MUSCULOSKELETAL DISEASE ASSESSMENT; OUTPATIENT; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS SEVERITY INDEX; RHEUMATOLOGIST; SEX; STEROID THERAPY; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DEMOGRAPHY; DRUG COMBINATION; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; UNITED STATES;

ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84928565978     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.11.1110     Document Type: Article

References (37)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25.
2. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003;48(10):2750-62.
3. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29(5):305-20.
4. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2000;39(1):28-33.
5. McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis. J Rheumatol. 2011;38(10):2141-49.
6. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39.
7. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69(6):976-86.
8. Yelin E, Tonner C, Kim SC, et al. Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. Arthritis Care Res (Hoboken). 2014;66(7):980-89.
9. Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2013;65(2):299-303.
10. DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther. 2009;31(8):1871-80.
11. Greenberg JD, Spruill TM, Shan Y, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013;126(12):1089-98.
12. Barnabe C, Thanh N, Ohinmaa A, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis. 2013;72(10):1664-68.
13. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1-10.
14. Danielson E. Health research data for the real world: the MarketScan databases. White paper. January 2014. Available at: http://truvenhealth.com/Portals/0/Users/031/31/31/PH_13434%200314_MarketScan_WP_web.pdf.Accessed September 30, 2014.
15. Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011;13(1):R32.
16. Jacobi CE, Triemstra M, Rupp I, Dinant HJ, Van Den Bos GA. Health care utilization among rheumatoid arthritis patients referred to a rheumatology center: unequal needs, unequal care? Arthritis Rheum. 2001;45(4):324-30.
17. Artz MB, Hadsall RS, Schondelmeyer SW. Impact of generosity level of outpatient prescription drug coverage on prescription drug events and expenditure among older persons. Am J Public Health. 2002;92(8):1257-63.
18. Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008;10(4):R95.
19. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-59.
20. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228-34.
21. Allison PD. Logistic Regression Using the SAS System: Theory and Application. Wiley-SAS Publishing; 2001.
22. Harrold LR, Harrington JT, Curtis JR, et al. Prescribing practices in a U.S. cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012;64(3):630-38.
23. Keystone EC, Breedveld FC, van der Heijde D, et al. Long-term effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014;41(1):5-14.
24. Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12):1558-65.
25. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319-31.
26. Polinski JM, Mohr PE, Johnson L. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis Rheum. 2009;61(6):745-54.
27. Solomon MD, Goldman DP, Joyce GF, Escarce JJ. Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med. 2009;169(8):740-48.
28. Karaca-Mandic P, Joyce GF, Goldman DP, Laouri M. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Serv Res. 2010;45(5 Pt 1):1227-50.
29. Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther. 2012;34(2):457-67.
30. Desai R, Agarwal S, Aparasu R. Drug utilization trends for arthritis and other rheumtic conditions and impact of patients' age on treatment choice. N C Med J. 2011;72(6):432-38.
31. Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65(9):1226-29.
32. Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33(2):234-43.
33. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;57(4):679-85.
34. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age? Rheumatology. 2006;45(12):1555-57.
35. Munson J, Morden N, Goodman D, Valle N, Wennberg J. The Dartmouth atlas of medicare prescription drug use. The Dartmouth Institute for Health Policy & Clinical Practice. October 15, 2013. Available at: http://www.dart-mouthatlas.org/downloads/reports/Prescription_Drug_Atlas_101513.pdf. Accessed September 22, 2014.
36. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.
37. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010;62(1):101-07.